Introduction
Chemotherapy regimens provided a means to control haematological malignancies but led to periods of neutropenia, during which patients were prone to systemic infections from multiple sources and a wide range of bacteria requiring empirical combination therapy with aminoglycosides, and the safer b-lactam antibiotics. These combinations offered synergistic activity by combining different modes of action according to Jean Klastersky and the EORTC. 1 Monotherapy was not an option in 1980 as no single agent had sufficiently broad activity and aminoglycosides had to be included to cover problematic bacteria such as Pseudomonas aeruginosa.
It was at this time that I was interviewed by Dr Roy Foord, the Medical Director at Glaxo Group Research in Greenford, near London, the site where William Perkin had established a dyestuffs industry that was a forerunner of the pharmaceutical industry.
I recall Dr Foord telling me that although I knew nothing about antibiotics, I spoke enthusiastically and clearly communicated my own research and he offered a chance of a clinical research position. My early experience was on late-stage studies and reports of cefuroxime, but there was excitement within the company about a novel broad-spectrum cephalosporin that was to become ceftazidime, or as we affectionately called it 'CAZ', which offered a significant enhancement of activity against P. aeruginosa and other Gram-negative bacilli. Gaps in my knowledge of microbiology were filled by Paul Harper, Peter Acred, Cynthia O'Callaghan and later, Anne Harris.
At an early stage, I had the distinction of having received more ceftazidime than any person on the planet; three intravenous courses, each of 10 days, giving multiple blood and urine samples and being lanced to measure my prothrombin time.
Ceftazidime had an initial scare when 3 of the first 11 patients treated suffered mild rash, but clinical trials were soon underway, and my role was to establish clinical studies in Austria, the UK and then Germany and the Netherlands. Initial studies were on urinary infections and pneumonia and on a 'serious infection' protocol as the dose was gradually raised from 500 mg three times daily to 2000 mg three times daily and experience extended to cystic fibrosis and even Pseudomonas meningitis.
At the Radboud hospital in Nijmegen, I established a study on ICU patients with Dr Roelof Van Dalen, in which we explored the pharmacokinetics in dialysis patients. On a routine visit to his clinic towards the end of 1981, I was checking his supplies and realized some vials were unaccounted for. These were the formative years of good clinical practice and upon questioning, he admitted that another doctor along the corridor had 'stolen' some of his supply. I set out to investigate and that was my first encounter with Dr Ben E. de Pauw. After I had reprimanded him, he shrugged his shoulders, arguing that he had taken ceftazidime to rescue patients who had failed on the usual EORTC regimens and he showed me that he had also stolen some of our 'stupid' case record forms (CRFs), presenting me with the most perfectly completed CRFs that I had ever seen.
I returned to London and explained to Roy Foord that I had discovered a new potential investigator, who although he had never really done clinical trials before, had documented his cases so well. The patients treated had received a combination of an aminoglycoside and cephalosporin, and were failing to respond, usually due to the isolation of Pseudomonas. Ceftazidime was added in place of cefotaxime. I recall that Roy was initially against a study, pointing out the lack of evidence for monotherapy, and yet I convinced him that the combination had failed and that ceftazidime replacing only one of the drugs was effectively acting alone. We reached a middle ground in which I drafted a protocol and de Pauw was allowed a pilot study of 30 cases using ceftazidime in combination with amikacin in patients who were still febrile after 48 -72 h of standard therapy.
On 3 February 1982, I summarized our experience with ceftazidime in neutropenics in a letter to Jim Chubb, whose team was setting up studies of ceftazidime in the USA in the newly established Research Triangle Park offices in North Carolina. This included the statement: 'de Pauw has used additional antibiotics in most cases so far but is now sufficiently impressed with ceftazidime to proceed with a trial of monotherapy'. A couple of his CRFs were included as evidence.
By this time in the UK we were broadening our experience, and other early investigators included a group led by Zamiri in Cardiff whose early experience was not so good, a serious infection study with Gozzard and Geddes in Birmingham that included some neutropenic patients and that led to a study that I had just established with Dr Mike Leyland's group in Birmingham, where I collaborated closely with Virginia Clough, and a study coordinated by Carolyn Davey-Smith with Duerden and Lilleyman in leukaemic children in Sheffield that had entered nine patients in a comparison with tobramycin plus azlocillin, though most did not have bacteria isolated. Two other studies about to start were with Rod Warren at Addenbrookes in Cambridge and with Bellingham in Liverpool (only 1 g 8 hourly). Early results in the USA had until then been 'less favourable'. Nevertheless, it was this early evidence that convinced the US team to establish a landmark study with Pizzo et al. 2 at NIH and to introduce other US studies with Bodey, Ramphal and Schimpf, and also with Feld in Canada.
Later in 1982, I established a study with Catovsky at the Hammersmith Hospital in London, working closely with their microbiologist Peter Donnelly, who through this experience met Ben de Pauw and eventually joined him in Nijmegen. In April 1982, I collated the overall experience for a letter that Roy Foord sent to Jean Klastersky setting out the updated experience and trying to persuade the EORTC to take up a monotherapy study. At the time, the EORTC were studying amikacin in combination with ticarcillin, azlocillin or cefotaxime.
Meanwhile in Nijmegen, I was joined by my colleague Theo Bothof in monitoring the progress of the first major randomized trial of ceftazidime monotherapy in which de Pauw et al.
3 compared ceftazidime with a combination of gentamicin and cefotaxime. We learnt a lot from those early studies, including the fact that the usual microbiological assessments of success and failure were not discriminatory and we introduced terms such as 'success with modification' and also gained the experience that on average an afebrile response could not be expected by 48 -72 h, but with confidence gained, monotherapy could be continued. It was important to have clear criteria for adding further antibiotics and to record which they were and why they were given.
This study, along with other experiences of monotherapy, was presented in the final session of the ceftazidime (Fortum) launch meeting at the Barbican in London in 1983 and subsequently published. The session was chaired by Klastersky with the opening words 'the most demanding trial of an antimicrobial that you can imagine is to give it to a granulocytopenic patient'. Other reports were by Reuben Ramphal, Phil Pizzo on cephalothin, gentamicin and carbenicillin versus ceftazidime as empirical therapy, Warren's group from Cambridge and Bodey from Houston.
The clinical development of ceftazidime had taken just 3 years and there was much excitement with the launch at the International Congress of Chemotherapy (ICC) meeting in Vienna later in 1983. Many of the investigators gathered and shared their experiences.
In order to evaluate the benefits of enhancing initial empirical Gram-positive cover, ceftazidime was compared with gentamicin combined first with flucloxacillin 4 and then cephalothin.
5
A further approach to this problem was taken with teicoplanin. 6 The latter study was presented at the ICC meeting in Kyoto in 1985 and it was while standing by a poster of the results that Richard Bax began to entice me to join what was then ICI Pharmaceuticals to repeat this work with a new drug that was to become meropenem. One of the minor irritations of ceftazidime was that it was formulated in such a way that reconstitution of the drug led to a release of carbon dioxide and the vials had to be vented to allow its release or otherwise it would fizz out of control. Nurses occasionally complained of being showered with the drug, which had the odour of cat urine. Ben was one of the few who published a study in neutropenics of a new arginine salt that circumvented this issue though the original remained a success and the arginine salt was never released. 7 Within the growing body of evidence with ceftazidime monotherapy, it became possible to examine subsections of the data and we reported on the treatment of pneumonia in immunocompromised patients, 8, 9 on 27 Pseudomonas infections treated between 1981 and 1984 and further extended in 1986, 10 and showed that ceftazidime did not enhance cyclosporine nephrotoxicity in bone marrow transplant patients. 11 One of the subinvestigators in Nijmegen at the time was Dr Stans Verhagen, who compiled a thesis based on his experience in the studies.
de Pauw continued to study ceftazidime further in wider collaborative studies. 12, 13 It was inevitable that I would return to Nijmegen by the time that meropenem was ready to be tested in neutropenic patients. Initially, we only planned a study of 200 patients with a parallel study planned in the USA. However, the Meropenem Study Group, which also included centres in Leuven and London, recruited their 200 patients before the USA study even started and so it was extended. The data were first presented at the Immunocompromised Host meeting in Colorado and subsequently published.
14 de Pauw and co-workers 15 also performed further collaborative studies with meropenem.
Of course many other antimicrobials have followed the monotherapy path and the EORTC and others have published many studies, not only on ceftazidime and meropenem, 16 but I hope my insight into the early studies at Glaxo and the significant role of Ben de Pauw are appropriate in the context of honouring his contributions in this area.
The role of monotherapy has been reviewed in the literature. 17 
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